Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model.
作者： Xiang Huang , Shiyun Cui , Yongqian Shu
DOI: 10.1007/S12026-015-8734-1
关键词:
摘要: The objective of this study was to investigate the immunomodulatory effect cisplatin (DDP) on frequency, phenotype and function myeloid-derived suppressor cells (MDSC) in a murine B16 melanoma model. C57BL/6 mice were inoculated with establish model randomly received treatment different doses DDP. percentages MDSC after DDP detected by flow cytometry. immunoinhibitory analyzed assessing immune responses cocultured effector through CFSE-labeling assay, detection interferon-γ production MTT cytotoxic respectively. Tumor growth survival monitored evaluate antitumor combined adoptive cytokine-induced killer (CIK) cell therapy. selectively decreased percentages, modulated surface molecules attenuated effects combination CIK therapy exerted synergistic against melanoma. downregulated frequency model, indicating potential mechanisms mediating its effect.
springer.com
sci-hub.se 参考文章(40)
Katherine H. Parker, Daniel W. Beury, Suzanne Ostrand-Rosenberg, Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Advances in Cancer Research. ,vol. 128, pp. 95- 139 ,(2015) , 10.1016/BS.ACR.2015.04.002
Alan J. Korman, Karl S. Peggs, James P. Allison, Checkpoint blockade in cancer immunotherapy Advances in Immunology. ,vol. 90, pp. 297- 339 ,(2006) , 10.1016/S0065-2776(06)90008-X
Yun-Sun Kim, Kyoo-A Lee, Chang-Yuil Kang, Hyun-Jeong Ko, Jung-Mi Lee, Yeon-Jeong Kim, Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted Into Immunogenic APCs With the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine Journal of Immunology. ,vol. 182, pp. 1818- 1828 ,(2009) , 10.4049/JIMMUNOL.0802430
Annie A Wu, Virginia Drake, Huai-Shiuan Huang, ShihChi Chiu, Lei Zheng, Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells OncoImmunology. ,vol. 4, pp. 1- 14 ,(2015) , 10.1080/2162402X.2015.1016700
Susanna Mandruzzato, Samantha Solito, Erika Falisi, Samuela Francescato, Vanna Chiarion-Sileni, Simone Mocellin, Antonio Zanon, Carlo R. Rossi, Donato Nitti, Vincenzo Bronte, Paola Zanovello, IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients Journal of Immunology. ,vol. 182, pp. 6562- 6568 ,(2009) , 10.4049/JIMMUNOL.0803831
Thomas F. Gajewski, The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment Seminars in Oncology. ,vol. 42, pp. 663- 671 ,(2015) , 10.1053/J.SEMINONCOL.2015.05.011
Maria Teresa P. de Aquino, Anshu Malhotra, Manoj K. Mishra, Anil Shanker, Challenges and future perspectives of T cell immunotherapy in cancer. Immunology Letters. ,vol. 166, pp. 117- 133 ,(2015) , 10.1016/J.IMLET.2015.05.018
Hong Qin, Beatrisa Lerman, Ippei Sakamaki, Guowei Wei, Soungchul C Cha, Sheetal S Rao, Jianfei Qian, Yared Hailemichael, Roza Nurieva, Karen C Dwyer, Johannes Roth, Qing Yi, Willem W Overwijk, Larry W Kwak, Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice Nature Medicine. ,vol. 20, pp. 676- 681 ,(2014) , 10.1038/NM.3560
Yazan S Khaled, Basil J Ammori, Eyad Elkord, Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunology and Cell Biology. ,vol. 91, pp. 493- 502 ,(2013) , 10.1038/ICB.2013.29
Xiang Huang, Yi-Tian Chen, Hai-Zhu Song, Gui-Chun Huang, Long-Bang Chen, Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World Journal of Gastroenterology. ,vol. 17, pp. 3002- 3011 ,(2011) , 10.3748/WJG.V17.I25.3002